Generic Name: lenvatinib
Drug Class: Targeted Therapy Medications
Approval Status: Experimental
Generic Version Available: No
Lenvima is a multikinase inhibitor approved for treatment of recurrent or metastatic thyroid cancer, previously treated kidney cancer and inoperable liver cancer.
Lenvima is a kinase inhibitor that blocks the action of several enzymes, including VEGFR, FGFR, KIT and RET, that play a role in cell growth and development of blood vessels that feed tumors.
Clinical trials showed that Lenvima slows disease progression in people with locally recurrent or metastatic thyroid cancer and previously treated kidney cancer. The Phase III REFLECT trial showed that Lenvima as first-line therapy improved progression-free survival in people with liver cancer. It was first approved in 2015.
Lenvima is taken as a once-daily capsule.
Common side effects include fatigue, diarrhea, nausea, loss of appetite, weight loss, high blood pressure, muscle or joint pain, skin rash, mouth sores and hand-foot syndrome (palmar-plantar erythrodysesthesia), with redness, swelling and pain on the palms of the hands and soles of the feet. Potential serious side effects may include severe hypertension, severe bleeding (hemorrhage), heart problems, blood clots in arteries, thyroid problems, liver toxicity and kidney toxicity with protein loss in the urine and slow wound healing. Lenvima may cause fetal harm if used during pregnancy.
For More Info: http://www.lenvima.com
Patient Assistance Program Info: http://www.eisaireimbursement.com/patient/lenvima/financial-assistance
Last Reviewed: December 15, 2018